Starling Oncology shared its third-quarter results, showing record sales of $169.8 million, up 24% from last year.

Nov 5, 2026, 5:55 PM ETResultsRead the original at Benzinga

Good for STLN

STLN's sales grew 24%, and adjusted EBITDA reached $3.4 million. Its balance sheet still needs work, but repeated positive profit and business growth support a stronger outlook.

STLN · Starling Oncology

AI read · Good for STLN

The AI's read

The second straight quarter of positive adjusted EBITDA suggests Starling is building a path to profit. Its Oregon contract adds about 40,000 Medicare Advantage members, and pharmacy sales grew 44%. Management still says it is working to steady its balance sheet. The repeated profit and business growth outweigh that remaining concern.

Get alerts for STLN

Follow Starling Oncology (STLN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for STLN

Free on the App Store and Google Play, or on the web.